Kardigan
- Market cap
- 1.29B
- P/E (TTM)i
- -4.48
- P/Bi
- 2.10
- EPSi
- -2.19
- Div yieldi
- 0.00%
- 52W posi
- 11%
Anonymous reader poll. Unscientific, not investment advice.
About Kardigan
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
- Founded
- 2023
- CEO
- Mr. Tassos Gianakakos
- Employees
- 380
- Headquarters
- Princeton, New Jersey, United States of America
- Fiscal year end
- 12-31
- Website
- kardigan.bio
Company profile
- Exchange
- US
- Symbol
- KARD
- Market-cap rank
- #3042
- Listing date
- 2026-06-18
- Market cap
- 1.29B
- Float cap
- 322.70M
- Shares out
- 93.50M
- Float shares
- 23.33M
Sectors & themes
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.